<DOC>
	<DOCNO>NCT00796991</DOCNO>
	<brief_summary>The purpose clinical research study learn pharmacokinetics Ipilimumab combine Paclitaxel/Carboplatin Dacarbazine</brief_summary>
	<brief_title>Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel , Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologic diagnosis advance malignant melanoma Eastern Cooperative Oncology Group ( ECOG ) performances status 01 Measurable/evaluable disease per modify World Health Organization ( mWHO ) criterion Evidence active brain metastasis Prior treatment anticytotoxic lymphocyte antigen 4 ( CTLA4 ) antiCD137 ( type tumor necrosis factor ) antibody Total Bilirubin great ( &gt; ) 1.5 * upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 * upper limit normal ( ULN ) Prior Autoimmune disease Use immunosuppressing therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Untreated Advanced Melanoma</keyword>
</DOC>